The Shape of Drugs to Come
In the days before biotechnology, the wide range of available medicines obscured the fact that nearly every drug had one thing in common with other drugs. With rare exceptions, medicines were based on chemical compounds that determined their safety and efficacy in patients.
The biotech industry opened the door to entirely new modalities that can be made through the marriage of science and the molecular machinery of cells. Today, protein engineers can reconfigure nature’s building blocks to design innovative structures that fight diseases in more sophisticated ways.
This ever-growing diversity of modalities has helped Amgen pioneer a new approach to drug discovery. This approach seeks to gain deep biological insights into diseases before selecting the optimal tool to target the key molecular defects.
To increase the likelihood of finding the best tool for the best target, Amgen has built an array of drug modalities that is unsurpassed in the biopharma industry.
In a new feature story on AmgenScience.com, you can now interact directly with each of these modalities and learn more about what makes each one unique.
In this new AmgenScience.com feature story, users can interact with Amgen’s industry-leading tool kit of drug modalities.